Eledon Pharmaceuticals, Inc.

NASDAQ: ELDN · Healthcare · Biotechnology

PublicHQ Irvine, CA · OrangeCIK 0001404281Reports USD

#1166 of 1,422 Healthcare companies by revenue

EA Score

39D

FH 52DQ 15GM —SS 57

v0.1 · 55/100 weight · provisional

↑ balance-sheet leverage, market scale · ↓ Piotroski F, disclosure history

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$45.6M

Employees

as of 2026-08-13

Market cap

$291.0M

as of 2026-08-13

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$0$02016

Net income-$45.6M-$45.6M2025

Operating income-$43.0M-$43.0M2023

Total assets$169.0M$169.0M2025

Liabilities$32.2M$32.2M2025

Equity$81.1M$81.1M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Eledon Pharmaceuticals, Inc.’s revenue?

Eledon Pharmaceuticals, Inc. booked $0 in FY2016 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.

Peers · Healthcare

SAB Biotherapeutics, Inc.52D Inhibikase Therapeutics, Inc.43D Zentalis Pharmaceuticals, Inc.40D Fulcrum Therapeutics, Inc.58C ALX Oncology Holdings Inc.37D CytoDyn Inc.30D

Neighbors

Orange →

Edwards Lifesciences Corporation$6.1B86A Chipotle Mexican Grill, Inc.$11.9B77B+Rivian Automotive, Inc.$5.4B38D TTM Technologies, Inc.$2.9B73B American Healthcare REIT, Inc.$2.1B56C The Ensign Group, Inc.$5.0B80B+

Key facts

CEODavid-Alexandre C. Gros

SectorHealthcare

IndustryBiotechnology

HeadquartersIrvine, CA

ExchangeNASDAQ: ELDN

Employees33

IPO date2014-09-17

Latest filings

10-Q2026-08-13 8-K2026-08-13 8-K2026-06-22 8-K2026-05-13 10-Q2026-05-13 DEF 14A2026-04-30 8-K2026-03-19 10-K2026-03-19

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.